CIAS
LGND icon

CBIZ Investment Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

CBIZ Investment Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$1.82K – 730
2025
Q2 		$1.82K Hold
16
– – ﹤0.01% 552
2025
Q1 		$1.68K Hold
16
– – ﹤0.01% 497
2024
Q4 		$1.71K Buy
+16
New +$1.81K ﹤0.01% 410

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CBIZ Investment Advisory Services's LGND Position: Q3 2025 in Review

CBIZ Investment Advisory Services sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 16 shares — an estimated $1.82K sold.

CBIZ Investment Advisory Services first reported a position in LGND in Q4 2024 and held it in 3 quarters. The position peaked at $1.82K in Q2 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • CBIZ Investment Advisory Services reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • CBIZ Investment Advisory Services sold 16 Ligand Pharmaceuticals shares in Q3 2025, an estimated $1.82K.
  • CBIZ Investment Advisory Services first reported a position in Ligand Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • CBIZ Investment Advisory Services's Ligand Pharmaceuticals position peaked at $1.82K in Q2 2025.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on CBIZ Investment Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.